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Enzyme replacement therapyPhenylketonuria (PKU) is an autosomal recessive genetic disease caused by defects in the phenylalanine hydrox-
ylase gene. Preclinical and clinical investigations suggest that phenylalanine ammonia lyase (PAL) could be an ef-
fective alternative for the treatment of PKU. The aim of this study is to investigate if erythrocytes loadedwith PAL
may act as a safe delivery system able to overcome bioavailability issues and to provide, in vivo, a therapeutically
relevant concentration of enzyme. Murine erythrocytes were loaded with recombinant PAL from Anabaena
variabilis (rAvPAL) and their ability to perform as bioreactors was assessed in vivo in adult BTBR-Pahenu2 mice,
the genetic murine model of PKU. Three groups of mice were treated with a single i.v. injection of rAvPAL-RBCs
at three different doses to select the most appropriate one for assessment of efﬁcacy. Repeated administrations
at 9–10 day-intervals of the selected dose for 10 weeks showed that the therapeutic effect was persistent and
not affected by the generation of antibodies induced by the recombinant enzyme. This therapeutic approach de-
serves further in vivo evaluation either as a potential option for the treatment of PKU patients or as a possible
model for the substitutive enzymatic treatment of other inherited metabolic disorders.
© 2014 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/3.0/).1. Introduction
Phenylketonuria (PKU; OMIM*261600) is the most common inborn
error of amino acid metabolism among Caucasians (overall incidence
1:10,000) caused by a deﬁciency of the enzyme phenylalanine
hydroxylase (PAH; EC 1.14.16.1) (OMIM*612349) that converts L-
phenylalanine (Phe) into tyrosine [1]. PAH defects result in Phe accu-
mulation in all tissues, including brain, and lead to severe neurological
and intellectual disability [1]. One of the current treatments is a rigorous
life-long Phe-restricted diet, necessary to keep an optimal cognitive
function [2]. Nevertheless, the diet implies some nutritional risks and
an obvious psychological burden, resulting in poor patient compliance
[3]. Another available treatment is sapropterin dihydrochloride
(Kuvan® BioMarin Pharmaceutical Inc., Novato, CA), a synthetic cofac-
tor of PAH approved for the treatment of PAH-deﬁcient subjects whor Sciences, University of Urbino
9 0722 305211; fax: +39 0722
ni).
. This is an open access article underproved to be responsive. However, many patients, especially those affec-
ted by the most severe defects, are not responsive to Kuvan® [4] and are
still in search of a medicament overcoming the limitations of diet.
Phenylalanine ammonia lyase (PAL; EC 4.3.1.24) is a non-
mammalian enzyme derived from the blue-green algae Anabaena
variabilis (Av) which is able to convert the essential amino acid Phe
into metabolically harmless trans-cinnamic acid and trace amounts of
ammonia [5]. rAvPAL chemically modiﬁed by polyethylene glycol
(rAvPAL-PEG) is an enzyme substitution therapy under investigation
(BioMarin Pharmaceutical Inc., Novato, CA) now in Phase III for patients
whose Phe levels are not adequately controlled by dietary therapy
or Kuvan® (see www.ClinicalTrials.gov; Government trial Identiﬁers:
phase I NCT00634660; phase II NCT00925054, NCT01560286,
NCT00924703 and NCT01212744; phase III NCT01819727 and
NCT01889862). Although PEG has been used to modify several thera-
peutic molecules (mostly enzymes) thanks to its ability to attenuate
the neutralizing immune response against the therapeutic agent [6],
concerns about PEG metabolism and accumulation in the organism
still remain [7–10], suggesting the usefulness of alternative strategiesthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
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straints the Phe-depleting enzyme may be loaded into circulating cells
with the advantage of protecting it from the immune reaction while it
carries out its own enzymatic activity on blood Phe. Several factors
make red blood cells (RBCs) an ideal delivery system for rAvPAL: a) a
protracted but predictable life-span; b) their biodegradability; c) their
biocompatibility and non-immunogenicity; d) procedures exist for the
transient opening of pores across the red cell membrane which permits
non-diffusible enzymes to be loaded inside RBCs [11–14]; and e) when
appropriate enzymes are entrapped, erythrocytes protect them from
rapid clearance and from the action of antibodies commonly elicited
in the patients upon repeated administrations [15,16].
Here we show that human and murine erythrocytes can be loaded
with different amounts of rAvPAL and have the ability to perform as en-
zyme reactors to metabolize Phe in vitro and to reduce the systemic Phe
concentration in BTBR-Pahenu2 mice. Two speciﬁc aims were pursued:
- to perform a dose range-ﬁnding investigation to determine the opti-
mal dose of rAvPAL-loaded RBCs (rAvPAL-RBCs) able to lower Phe to
safe levels;
- to assess the effectiveness of repeated administrations of rAvPAL-
RBCs in BTBR-Pahenu2 mice to maintain low levels of blood Phe de-
spite potential immunological host response.
2. Materials and methods
2.1. Animals
Adult homozygous BTBR-Pahenu2 and wild type (WT) mice were
employed in this study. Their use was approved by the Ethical Commit-
tee for Animal Experiments of the University of Urbino “Carlo Bo”-Italy
(Prot. CESA 3/2012). Animals were fed on Teklad global 18% protein ro-
dent diet (Harlan Laboratories Inc., Madison, WI).
2.2. rAvPAL
Recombinant AvPAL was prepared by the BioMarin clinical
manufacturing group. Two lots of recombinant protein were used,
whose speciﬁc activity (SA)were 1.8 IU/mg and1.54 IU/mg, respectively.
2.3. Development of human rAvPAL-RBCs for preliminary in vitro studies
Human bloodwas obtained from the Blood Transfusion Center of the
Hospital “S. Maria della Misericordia”, Urbino (PU) Italy; bloodwas pro-
vided byhealthy adult volunteerswho signed an informed consent form
before donation and samples were collected anonymously in heparin-
ized tubes. The use of human blood in the present study was approved
by the research ethics committee of the University of Urbino (PU), Italy.
rAvPAL (SA 1.8 IU/mg) was loaded into human RBCs bymeans of hypo-
tonic dialysis, isotonic resealing and “reannealing”, essentially according
to Magnani et al. [17] with these modiﬁcations: RBCs were loaded with
increasing amounts of enzyme by adding rAvPAL in the 6–29 IU range to
RBC suspensions at ﬁxed 70% hematocrit (Ht) in physiological saline so-
lution containing 10 mMHEPES (pH 7.4), 154 mMNaCl and 5 mM glu-
cose (Hepes solution). Each condition (1 ml ﬁnal volume) was dialyzed
at+4 °C in a cellulose tube (14 kDa cut-off) vs 50ml of hypotonic solu-
tion 60 mOsm measured by Osmometer Fiske Associates Model 210,
Norwood, MA, USA. After dialysis the cells were approx. 90 mOsm. To
determine the best loading conditions to be used during the dialysis
step, RBCs were re-suspended at Ht range 40–70% in Hepes solution in
the presence of ﬁxed 29 IU rAvPAL. Unloaded (UL) RBCs (i.e. cells sub-
mitted to the same procedure without the addition of the enzyme)
were used as controls. The amount of entrapped rAvPAL was quantiﬁed
essentially by a kinetic assay as previously described [18]. Hematologi-
cal parameters were measured by an automatic Coulter AcT 5 Diff He-
matology Analyzer (Beckmann, Miami, FL). Percent RBC recovery wascalculated from the number of RBCs submitted to the dialysis step and
those recovered at the end of the loading procedure.
2.4. Evaluation of phenylalanine metabolism by rAvPAL-RBCs
Enzyme-loaded and UL RBCs were incubated in Hepes solution with
2000 μM Phe to a ﬁnal Ht of 40% at 37 °C for up to 60 min. At planned
intervals (0, 30 and 60 min), 40 μl (in duplicate) was spotted on ﬁlter
paper (Whatman903), dried and processed for Phe determination by
tandemmass spectrometry (MS/MS).
2.5. Development of murine rAvPAL-RBCs for preliminary in vitro studies
Bloodwas collected fromCO2 anesthetized control BTBR-WTmice by
puncture of the retro-orbital sinus in heparinized tubes and murine
RBCs were essentially processed as previously described for human
RBCs. To maximize rAvPAL loading into RBCs, 24 IU, 42 IU and 54 IU of
enzyme (SA 1.8 IU/mg) were added to RBC suspensions at 60%, 50%
and 40% Ht respectively. It must be noticed that only by decreasing
RBC Ht, a greater volume was available for enzyme addition. Each con-
dition was dialyzed 1 h at 4 °C vs dialysis buffer optimized for murine
RBC loading: 15mMNaH2PO4, 15 mMNaHCO3, pH 7.4, 20 mM glucose,
4 mMMgCl2, 3 mM glutathione, and 2 mM ATP (85 mOsm). After dial-
ysis the cells reached about 105 mOsm. Subsequent steps were then
carried out as described for human cells and the amount of entrapped
protein was determined as reported [18].
2.6. Loading procedure and in vivo efﬁcacy of rAvPAL-RBCs: dose ﬁnding
study
In this step, 42 IU rAvPAL (400 μl of protein solutionwith SA 1.54 IU/
mg)was added to 600 μl of packedRBCs to obtain 1mlof erythrocytes at
50% Ht and dialyzed as described. This procedure was carried out for 15
separate dialysis tubes. At the end, all RBC suspensions were pooled
(ﬁnal volume 15 ml) and allowed to equilibrate 5 min at 37 °C under
gentle stirring. At this stage the cells reached 102 mOsm. After resealing
and re-annealing steps, loaded erythrocytes were washed twice in
Hepes solution at 450 g for 10min to remove the unentrapped enzyme.
The expression of phosphatidylserine (PS) on RBC surface was evaluat-
ed immediately after the loading procedure by annexin V binding (see
after). rAvPAL-RBCs were then re-suspended in Hepes solution at 36%
Ht (ﬁnal volume 3.5 ml) and checked for the amount of encapsulated
protein before injection into BTBR-Pahenu2 mice (mean body weight
25.64 ± 9.47 g). rAvPAL-RBCs were prepared at 36%, 18% and 9% Ht
(corresponding to approx. 4.75, 2.37 and 1.18 IU rAvPAL/ml, respective-
ly), in order to administer the scheduled doses to the mice in the same
volume (250 μl).
Three different doses of enzyme-loaded RBCs were administered to
three cohorts of BTBR-Pahenu2 mice by i.v. injection so that each cohort
received 0.25 IU (n = 5 mice), 0.5 IU (n = 6 mice) and 1 IU (n = 3
mice) of rAvPAL, respectively. The efﬁcacy of the treatmentwas evaluat-
ed by biochemical monitoring of blood Phe, sampling blood at time 0,
and then 1, 2, 5, 8, 12, 16, and 21 days after a single injection. Blood
(40 μl) was collected from the submandibular vein by special animal
lancets (Goldenrod 5.5 mm, Braintree Scientiﬁc Inc., Braintree, MA)
after 2 h of food deprivation, spotted on ﬁlter papers and analyzed by
MS/MS for Phe levels.
2.7. Loading procedure and in vivo efﬁcacy of rAvPAL-RBCs: repeated
administrations
For the repeated administration studies, 42 IU rAvPAL (SA1.54 IU/mg)
was added to packed RBCs (85.5± 7.1% Ht) to obtain 1ml at 49± 2%Ht,
and dialyzed 75 min at 4 °C (dialysis buffer for murine use 81.75 ±
2.31 mOsm), obtaining an osmolality of 108.5 ± 5.9 mOsm. The following
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carried out as described above.
Packed loaded RBCs were re-suspended in Hepes solution at approx.
20% Ht in order to administer 0.67± 0.07 IU/mouse in a ﬁnal volume of
180±43 μl (step 1) or approx. 200 μl (step 2), an amount of enzyme ac-
cording to that suggested by the “dose ﬁnding” in vivo study. In both
steps, BTBR-WT (n = 5) and BTBR-Pahenu2 (n = 5) mice were used as
controls and received repeated injections of Hepes solution following
the same schedule as the RBC-treated mice.
Phe was evaluated by MS/MS analysis of blood spots and sam-
ples were also drawn from control healthy and BTBR-Pahenu2
mice. Blood samples (100 μl) for anti-rAvPAL IgG analysis were
collected in heparin from the submandibular vein at different
times from RBC infusion: time 0 (before each administration)
then 9–10 and 13–14 days post i.v. (step 1); only at time 0 (before
each RBC injection) for step 2. In both steps, plasma was collected
21 days post last infusion, too.2.8. Tandem mass spectrometry
RBC suspensions and mouse whole blood were collected on
Schleicher&Schuell 903 grade ﬁlter paper, dried under ambient condi-
tions and stored at 4–8 °C in plastic bags. The analysis of Phe in the
dried blood spots (DBS) was performed using a previous method [19]
with somemodiﬁcations. Threemillimeter diameter dotswere punched
out and eluted in 100 μl of methanol/water (80:20) solution containing
labeled amino acid internal standards (CIL, Andover, MA, USA). The
samples were shaken for 30 min at 30 °C. Then 65 μl of supernatant
was dried under nitrogen ﬂow at 45 °C. The residues were treated
with 50 μl of 3 M hydrochloric acid in n-butanol solution at 60 °C for
30 min. After derivatization, the samples were dried under nitrogen
ﬂow at 45 °C and recovered in 70 μl of acetonitrile/water (80:20)
containing 0.1% formic acid. Twenty microliters was injected into
a LC-MS/MS system (API 2000, Sciex, Toronto, Canada). A Series
200 micro pump (PerkinElmer, Norwalk, CT, USA) and a Series
200 autosampler (PerkinElmer) were used for solvent delivery
and automated sample loading. The mobile phase was acetonitrile/
water (80:20) at a ﬂow rate of 50 μl/min. Neutral loss scan of
102 Da fragmentwas used for the detection of Phe. The total acquisition
time was 2 min.2.9. Evaluation of plasma anti-rAvPAL IgG levels
IgG levels were evaluated by standard indirect ELISA. Plasma was
obtained from blood samples and tested by standard indirect ELISA
employing rAvPAL as antigen (1 μg/ml in 50 mM carbonate buffer,
pH 9.7). Samples were serially diluted in the range of 1:50–1:200 for
pre-treatment plasma and 1:400–1:409,600 for post-treatment plasma
and tested in duplicate. The immune complexes were revealed by a
chromogenic reaction.Table 1
Optimization of rAvPAL loading into human RBCs.
RBC dialysis Ht Added rAvPAL (IU) Loaded rAvPAL (IU/ml RBCs) RBC r
a) 70% 6 1 81
b) 70% 12 1.3 77
c) 70% 24 1.5 75
d) 70% 29 2.4 66
e) 60% 29 3.3 72
f) 50% 29 4.4 62
g) 40% 29 10.1 50
Reference values for human erythrocytes
(range)a
a Reference ranges are the minimum and maximum values observed in human blood before2.10. Annexin V staining
Annexin V was used as a probe to detect cells that have exposed
phosphatidylserine on the surface, an event associated with cell death
or membrane damage. Positive RBCs were counted by ﬂow cytometry
as previously described [20].
2.11. Statistical analysis
Blood Phe levels were analyzed by 2-way ANOVA (dose ﬁnding
study) or by one-way ANOVA (repeated administration studies).
3. Results
3.1. In vitro studies
3.1.1. Development of human rAvPAL-RBCs and Phe metabolism
Human RBCs loaded with increasing quantities of protein were ob-
tained both by adding increasing amounts of enzyme during the encap-
sulation procedure (Table 1, a–d) and by varying RBCHt (range 70–40%,
Table 1, d–g) in the presence of a ﬁxed amount of rAvPAL (29 IU). Both
strategies were effective in modulating the encapsulated protein. The
most efﬁcient procedure provided approx. 10 IU/ml packed cells,
when the highest amount of protein (29 IU) together with the lowest
RBC Ht (40%) was used. RBC recovery and hematological parameters
were also investigated: by decreasing the RBC Ht, cell recovery is re-
duced; however, at the end of the loading procedures, a recovery higher
than 50% could always be achieved for all the tested dialysis conditions.
RBC corpuscular indices (MCV, MCH, MCHC) of rAvPAL-RBCs are in
agreement with those of native cells (reference values) for the 70% Ht
conditions, whereas the differences are more pronounced when Ht
was reduced during dialysis. Accordingly, RDW values, too, differ from
reference, particularly at the lowest Ht.
As concerns the ability of human rAvPAL-RBCs (Table 1, d–g) to me-
tabolize Phe, the cells proved to be very efﬁcient even at the lowest dose
of encapsulated enzyme (2.4 IU/ml packed RBCs), condition at which
80% Phe was metabolized after 30 min incubation at 37 °C. At the
same time point, Phe totally disappeared in the presence of the highest
dose of loaded enzyme (10.1 IU/ml packed RBCs). After 1 h at 37 °C, Phe
was completely metabolized even by RBCs loaded with 4.4 IU/ml
packed cells; at this incubation time, Phe was below 200 μM in all the
tested conditions.
3.1.2. Development of murine rAvPAL-RBCs and Phe metabolism
To provide the necessary information for preclinical investigations,
the best experimental condition to load rAvPAL in murine RBCs was de-
termined. The results reported in Table 2 show that, like human cells,
mouse RBCs could be loaded with increasing amounts of rAvPAL by
varying RBC Ht and protein concentration. However, when compared
to human RBCs, the recovery percentage was much lower. The corpus-
cular indices revealed values for murine rAvPAL-RBCs not signiﬁcantly
different from reference values (for dialysis at 60% and 50% Ht); itecovery (%) MCV (μm3) MCH (pg) MCHC (g/dl) RDW (%)
84 24.9 29.6 21.6
89 26.2 29.4 20.8
88 26.3 29.7 20.9
81 23.9 29.5 24.3
83 23 27.7 23.4
82 21.4 26.1 25.6
82 16.1 19.6 35.4
80–97 26.5–33.5 31.5–35 10–15
being submitted to the loading procedure. Results are from a single experiment.
Table 2
Optimization of rAvPAL loading into murine RBCs.
RBC dialysis Ht Added rAvPAL (IU) Loaded rAvPAL (IU/ml RBCs) RBC recovery (%) MCV (μm3) MCH (pg) MCHC (g/dl) RDW (%)
a) 60% 24 3.15 28 43 16.6 38.3 18.4
b) 50% 42 8.06 29 40 18.5 34.6 18.8
c) 40% 54 15.62 18 42 9 21.3 20.1
Reference values for murine erythrocytes
(range)b
48 16.8–18.1 34.7–37.7 14.5–15.2
b Reference ranges are the minimum and maximum values observed in murine blood before being submitted to the loading procedure. Results are from a single experiment.
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values not comparable to native cells, conﬁrming that this condition
is too strong for the fragility characteristics of murine RBCs. Phe
metabolism was evaluated as for human cells; murine RBCs loaded
with different rAvPAL doses (3.15, 8.06 and 15.62 IU/ml packed
cells) were able to metabolize 72–80% of Phe after 1 h of incubation
at 37 °C.
3.2. In vivo efﬁcacy of rAvPAL-RBC treatment: dose ﬁnding study
This study was performed to test the ability of different doses of
rAvPAL-RBCs to reduce blood Phe concentration in BTBR-Pahenu2
mice. Based on the results in vitro, condition b shown in Table 2
was selected. A bulk loading procedure was used, at the end of
which 2.34 ml of RBCs at 54% Ht loaded with 16.7 IU of rAvPAL was
obtained (corresponding to 13.2 IU rAvPAL/ml packed RBCs). Differ-
ences between loaded RBCs of in vitro and in vivo studies are likely
due to intrinsic cell variability among animals. The cells positively
stained with annexin V increased from 0.3% in basal conditions to
1.5% after the procedure. The evaluation of the in vivo effect of
rAvPAL-RBCs yielded the results shown in Fig. 1.
Phe levels before treatment were 1186 ± 342, 1221 ± 149 and
1292 ± 211 μM in groups that received 1, 0.5 and 0.25 IU/mouse re-
spectively, and were not signiﬁcantly different (p N 0.05). All the
doses of enzyme caused Phe to dramatically decrease in the ﬁrst hours
after treatment, with peak values of respectively 54.8 ± 90.5, 5.6 ± 6
and 57.1 ± 56 μM after 24 h. However, with 0.25 IU rAvPAL, Phe slowly
returned toward basal levels reaching on day 8 roughly 50% of the pre-
treatment values. For the two highest doses, the effect remained maxi-
mal for the ﬁrst 5 days after infusion, with slow return to basal levels
(both approx. 21% of their respective basal values on day 8). On day 8,
the effect of these two doses was statistically superior (p b 0.05) to
that of the lowest dosewhile between them therewasno signiﬁcant dif-
ference. On day 12, Phe was similar in the three groups (74%, 73%, andFig. 1. Blood Phe concentrations before and after rAvPAL-RBC injection. Mice received 1 (n= 3
different between 0.5 IU and 1 IU rAvPAL, whereas a signiﬁcantly lesser effect was observed in
ANOVA followed by Tukey's test, *p b 0.05). All doses were signiﬁcantly effective until 8 days p68% of basal values, with 0.25, 1 and 0.5 IU/mouse, respectively). More-
over, Phe levels were signiﬁcantly lower (p b 0.05) than basal values
through 8 days post treatment in every group.
3.3. In vivo efﬁcacy of rAvPAL-RBC treatment: repeated administrations
We assessed the effect of repeated administrations of rAvPAL-RBCs
with a dose of at least 0.5 IU/mouse (minimum administered dose).
The aims were: a) assessment of efﬁcacy of three subsequent infusions
of rAvPAL-RBCs at 18 day-intervals and evaluation of themost appropri-
ate time-lag between the subsequent injections in order to keep blood
Phe in a potentially safe range (step 1); b) assessment of efﬁcacy of
seven administrations of loaded RBCs at 9–10 day-intervals (step 2);
and c) exploration of the speciﬁc immune response against rAvPAL in
mice treatedwith rAvPAL-RBCs (step 1 and step 2). Themain properties
of loaded RBCs used in these studies are shown in Table 3.
3.3.1. Efﬁcacy of three rAvPAL-RBC injections at 18–19 day-intervals in
BTBR-Pahenu2 mice
Five BTBR-Pahenu2 mice were treated with three i.v. injections of
0.67 ± 0.07 IU/mouse rAvPAL-RBCs (an amount of enzyme according
to that suggested by the “dose ﬁnding” study) at 18–19 day-intervals.
The results reported in Fig. 2a show that the injected rAvPAL-RBCs are
able to decrease blood Phe levels to values near normality 4–5 days
after each treatment, while, after 13–14 days, Phe returns to the initial
values. Data were also graphed by Box-and-Whiskers plot (Fig. 2b)
and suggest 9–10 days as the longest possible time interval between ad-
ministrations capable ofmaintaining blood Phe at concentrations signif-
icantly lower than pathological.
Phe excess inhibits metabolic pathways dependent upon tyrosine,
such as melanin production. By reducing Phe, this pathway is restored
as illustrated by the fur darkening of a mouse involved in step 1
(Fig. 3), potentially representing a decrease in Phe-mediated pathology.), 0.5 (n= 6) and 0.25 (n= 5) IU rAvPAL-RBCs. The treatment efﬁcacy is not signiﬁcantly
mice receiving 0.25 IU, compared to the other two doses, 8 days post treatment (by 2-way
ost treatment (by 2-way ANOVA followed by Dunnett's test, p b 0.05 vs pre-treatment).
Table 3
Features of murine rAvPAL-RBCs of the in vivo repeated administration study, step 1 and step 2.
Loaded rAvPAL (IU/ml RBCs) RBC recovery (%) MCV (μm3) MCH (pg) MCHC (g/dl) RDW (%) Annexin V (%)
Step 1
(n = 3)
17.2 ± 5.69 49 ± 10.45 37 ± 1.83 12.2 ± 1.47 32.88 ± 2.95 17.53 ± 0.47 5.03 ± 1.55
Step 2
(n = 7)
17.97 ± 4.2 45.79 ± 11.3 37.14 ± 1.86 12.69 ± 2.12 33.79 ± 4.34 18.01 ± 0.91 4.6 ± 1.1
Control erythrocytes (range)c 48–50 16.5–22.2 33.7–45 13.6–15 1.3 ± 0.4
c Reference ranges are the minimum and maximum values observed in overall murine blood before being submitted to the loading procedure. Data are means ± SD. n = number of
independent loading procedures.
Fig. 2. Blood Phe levels in controlmice and BTBR-Pahenu2mice treatedwith rAvPAL-RBCs at 18–19 day-intervals. (a) Time-course representation ofmean Phe values± SD of control (n=5
for both control groups) and treated mice (n=5). (b) Box-and-Whiskers plot of Phe values in control (Ctrl) and treated mice; the effect was signiﬁcant by one-way ANOVA followed by
Dunnett's test (p b 0.05 vs before treatment) up to 9–10 days post RBC injections. Control mice received i.v. injections of Hepes solution.
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(Fig. 4), the presence of antibodies did not modify the ability of loaded
RBCs to reduce blood Phe. In fact, as expected, the ﬁrst infusion hadmin-
imal effect on IgG production, while subsequent injections resulted in a
strong and increasing boost in the immune response.
3.3.2. Efﬁcacy of seven rAvPAL-RBC injections in BTBR-Pahenu2 mice
Eight BTBR-Pahenu2 mice received seven infusions of 0.67 ±
0.07 IU/mouse rAvPAL-RBCs at 9–10 day-intervals. Blood Phe and
anti-rAvPAL plasma IgG were monitored during the whole experimen-
tal period. Results reported in Fig. 5a and b show that the seven
rAvPAL-RBC injections were able to maintain blood Phe to valuesbetween those of healthy control mice (115.30 ± 50.40 μM)
and those of BTBR-Pahenu2mice (1137.99 ± 127.19 μM) for the dura-
tion of the study. All the infusions were able to signiﬁcantly decrease
Phe to a similar extent, reaching values similar to those of healthy
mice 4–5 days after each treatment and returning to 65% of pre-
treatment values 9–10 days after each i.v., thus conﬁrming what pre-
viously seen (step 1). In addition, when the efﬁcacy of the treatment
was evaluated for the whole duration of the experiment (from day 0
to day 70) by estimating the AUCs, a reduction of 51.6% in blood Phe
was observed.
Like the 3-dose study, mice treated more frequently with
rAvPAL-RBCs restored fur pigmentation, indicating a restoration
Fig. 3. Fur pigmentation of a BTBR-Pahenu2 mouse involved in step 1 of the “Repeated administration” study. Pictures were taken at time 0 before infusions (left), 9 days after the 2nd i.v.
(middle) and 20 days after the 3rd i.v. of rAvPAL-RBCs (right).
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generally increased after each infusion (Fig. 6), peaking at a similar
titer as seen in step 1. The presence of anti-rAvPAL antibodies did
not modify the efﬁcacy of enzyme-loaded RBCs in removing blood
Phe after several administrations.4. Discussion
We have demonstrated that rAvPAL-RBCs act as bioreactors able to
decrease blood Phe in vitro and in vivo in BTBR-Pahenu2 mice, a widely
used animal model of human PKU. Clinical studies have shown that
RBCs are ideal carriers to deliver therapeutic enzymes in circulation
and can protect them from premature inactivation both by plasma pro-
teases and by neutralizing antibodies, when repeated administrations
are needed [15,16]. Starting from these results, the same strategy was
employed here to treat PKU. In preliminary in vitro studies, the best con-
ditions to load rAvPAL in human and murine RBCs were developed. The
results showed that it is possible to loaddifferent amounts of enzymeby
varying both the RBC hematocrit and the enzyme concentration during
the dialysis step. Up to now, RBCs loaded with different quantities of
protein were obtained only by adding the latter in increasing amounts
during the dialysis [21]. Therefore, this is the ﬁrst evidence of the
possibility to modulate the ﬁnal protein content by acting on Ht values
too.
Human and murine rAvPAL-RBCs showed a pronounced ability to
metabolize Phe as expected from the Phe uptake kinetics [22]. There-
fore, differences in Phe metabolism were due to the different amount
of loaded enzyme. To evaluate the preclinical efﬁcacy of the strategy,
the experimental conditions were set at three enzyme doses (1, 0.5
and 0.25 IU rAvPAL/mouse). As far as in vivo efﬁcacy is concerned, all
the doses of enzyme delivered by RBCs were able to dramatically de-
crease blood Phe in the ﬁrst hours after treatment with no differences
among doses. The lowest one (0.25 IU/mouse) however, appeared toFig. 4. Median antibody titers of BTBR-Pahenu2 mice treated with rAvPAL-RBCs at 18–
19 day-intervals (step 1, n=5). Blood samples were collected at time 0 before each infu-
sion and at time 9–10 days and 13–14 days post infusion. Samples were collected on day
21 after the last treatment, too. On the basis of the results so far obtained, a longer term
study with more frequent dosing was performed.have a shorter duration of action, as Phe started to return toward
basal concentrations on day 2 and reached roughly 50% of the pre-
treatment values on day 8. The other two doses (0.5 and 1 IU/mouse)
seemed to be both supramaximal. These results suggest that the dura-
tion of action of the treatment is determined by the clearance of loaded
erythrocytes from circulation. In fact, the half-life of loadedmurine RBCs
has been repeatedly reported to be in the range of 6–11 days [23–25],
slightly reduced in comparison with native cells (range 12–14 days
[23,26]), due to a minimal loading-induced damage. These data overall
demonstrate that blood Phe levels can effectively be modulated in vivo
by injection of rAvPAL-RBCs and, moreover, they allow the selection of
a proper schedule of repeated treatments for long term control of hy-
perphenylalaninemia in BTBR-Pahenu2 mice. As expected, once rAvPAL
is administered through RBCs three times every 18–19 days, the pres-
ence of plasma anti-rAvPAL IgG does not modify the enzyme activity.
Similar rates of Phe reduction were observed among injections follow-
ing the repeated administrations in spite of the increasing levels of
anti-rAvPAL IgG. The subsequent seven infusions of rAvPAL-RBCs
(0.67 ± 0.07 IU/mouse) at 9–10 day-intervals proved to be able to re-
duce blood Phe to levels signiﬁcantly lower than their corresponding
starting values during thewhole experiment (70 days). Moreover, a re-
versal of hypopigmentation was observed, conﬁrming what was previ-
ously reported by Sarkissian [27] in which BTBR-Pahenu2 mice were
treated with weekly s.c. injections of rAvPAL-PEG (4 IU for 10 weeks
and then 2 IU for 6 weeks). This result was probably due to the reduced
inhibition of tyrosinase caused by the excess of blood Phe in PKUdisease
[28]. It has to be highlighted that in the present work the reversal of
hypopigmentation was observed following less frequent injections of
a lower dose of enzyme.
In our studies, comparisons with free and/or rAvPAL-PEG were not
performed since authoritative and detailed literature in this ﬁeld
had already been produced [27] showing the advantages of
PEGylation. Moreover, Sarkissian et al. clearly indicated how the
administration of decreasing doses of the PEGylated enzyme per-
mits to reduce immunogenicity, thus emphasizing the importance
of protection against the immune reaction. In our study, a better ef-
ﬁcacy (Phe range 100–900 μM) was attained by the i.v. administra-
tion of approx. half the dose every 9–10 days compared to the
lowest dose employed by Sarkissian et al., which resulted in blood
Phe in the range 500–1200 μM [27].
In addition, a very recent work by Longo et al. [9] (clinical trial
NCT00925054) shows that a single s.c. injection of rAvPAL-PEG in PKU
patients induced the production of antibodies both against PEG and
rAvPAL and caused some moderate hypersensitivity adverse events,
even though the treatment was generally fairly well tolerated. While
this important study conﬁrms the efﬁcacy of a single s.c. bolus of
rAvPAL-PEG in reducing blood Phe (at a dosage of 0.1 mg/kg) in adult
PKU patients, the effect of repeated dosing as concerns immunological
reaction and enzymatic activity remains to be explored. In the experi-
mental setting we settled, the erythrocyte-based approach seems to
overcome some problems associated with s.c. injection of the enzyme
while ensuring a persistent therapeutic effectiveness.
The administration of PAL by carrier RBCs as a therapy for PKU was
ﬁrst proposed by Sprandel et al. in 1990 [29] with a short-term study
Fig. 5. Blood Phe levels in BTBR-Pahenu2mice treated with rAvPAL-RBCs at 9–10 day-intervals. a) Time-course representation of mean Phe values ± SD of control (n=5 for both control
groups) and treatedmice (n=8). b) Box-and-Whiskers plot of Phe values in control (Ctrl) and treatedmice; for thewhole duration of the study (10 weeks), rAvPAL-RBC injectionsmain-
tained Phe at levels signiﬁcantly lower than their starting condition (by non parametric ANOVA followed by Dunn's test, p b 0.05). The set named “During treatment” comprises all values
from day 4 post 1st i.v.to day 14 post 7th i.v. Control mice received i.v. injections of Hepes solution.
43L. Rossi et al. / Journal of Controlled Release 194 (2014) 37–44demonstrating the effectiveness of the strategy. Recently, PAH-loaded
RBCs were proposed for the same purpose [30] but, unfortunately,
they were unable to lower Phe when administered to BTBR-Pahenu2
mice, thus revealing the superiority of rAvPAL-RBCs in reaching the
objective.Fig. 6.Median antibody titers of BTBR-Pahenu2mice treatedwith rAvPAL-RBCs at 9–10 day-
intervals (step 2, n=8). Blood samples were collected at time 0 before each infusion and
on days 10 and 21 after the last infusion.Moreover, it is noteworthy that an electromedical device (named
Red Cell Loader©) capable of processing, in aseptic and pyrogen-free
conditions, a small volume of autologous erythrocytes to be re-infused
into the same donor, is already in clinical use (www.erydel.com). In
fact, clinical studies have been performed employing dexamethasone
21-P-loaded-RBCs generated by the “Red Cell Loader” equipment for
the treatment of different diseases [31–35].
5. Conclusions
Our data indicate rAvPAL-RBCs as a potential treatment for PKU pa-
tients. As demonstrated here, proteins can be loaded into RBCs, thus
opening new perspectives for the development of enzyme replacement
therapies for disorders involving enzymatic deﬁciencies. Other inborn
errors of metabolism, which share with PKU a similar pathophysiologi-
cal mechanism and are characterized by a progressive blood accumula-
tion of toxic compounds [36], could beneﬁt from the biotechnological
approach here described.
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